Trial · NCT00790868

Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder

NCT00790868, Phase 2, Completed, Boston University Charles River Campus; results first posted 2018-03-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder. Trials, record NCT00790868. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00790868

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
NCT number: NCT00790868
Status: Completed
Phases: Phase 2
Enrollment: 180 participants, actual
Lead sponsor: Boston University Charles River Campus
Conditions: Panic Disorder
Interventions: d-cycloserine, placebo
First posted: 2008-11-14
Last updated: 2018-03-07
Results first posted: 2018-03-07
Limitations and caveats: The investigators did not systematically collect fear estimates across exposure and are therefore unable to examine this factor as a moderator.~Unexpected site effects were observed for several of our outcome variables.

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Panic Disorder Severity Scale (PDSS)	baseline, mid-TX, post-TX, follow-up visits 1-4	The percent change in PDSS score from baseline to the relevant assessment points is the continuous primary outcome measure. The PDSS consists of seven items, each rated on a 0 to 4 scale (0 denoting none, and higher ratings reflecting greater degrees of symptom severity; for a possible range in scores from 0 to 28). In the tabular data below we present the total scores (sum of items).
Primary	Remission Status	Pre-treatment, Post-Treatment, and each follow-up sessions	Remission status will be used as the primary categorical outcome variable. The CGI-S was used in determining whether patients met the "CGI-S of 1 or 2" component of the "remission status" criteria (i.e., zero panic attacks and CGI-S of 1 or 2 at endpoint). No values are missing because remission must be confirmed; missing status is assigned to disorder status. Hence results are for the full randomized sample.
Secondary	Depression Severity	Baseline, Tx Endpoint, Each of 4 follow-up assessments	Depression severity was assessed with the MADRS, with scores ranging from 0 to 60. Higher scores indicate greater depression.
Secondary	Quality of Life Ratings	Baseline, Tx Endpoint, Each of 4 follow-up assessments	Quality of life as assessed by the Q-LES-Q. Scores range from 14-70 for total raw score, higher scores indicate higher quality of life ratings.
Secondary	Role Functioning	Baseline, Tx Endpoint, Each of 4 follow-up assessments	LIFE-RIFT. For this clinician-rated measure, total scores range from 0 to 20, with higher scores indicating greater impairment

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Panic Disorder Severity Scale (PDSS)	baseline, mid-TX, post-TX, follow-up visits 1-4	Seventeen subjects out of 92 (five during treatment and 12 during follow-up, 20% total) in the control group compared to six out of 88 (four during treatment and two during follow-up, 10% total) in the DCS group dropped out.	units on a scale	MEAN
PRIMARY	Remission Status	Pre-treatment, Post-Treatment, and each follow-up sessions	Full sample of 180 randomized participants	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Depression Severity	Baseline, Tx Endpoint, Each of 4 follow-up assessments	Randomized participants with panic disorder	units on a scale	MEAN
SECONDARY	Quality of Life Ratings	Baseline, Tx Endpoint, Each of 4 follow-up assessments	Randomized participants	units on a scale	MEAN
SECONDARY	Role Functioning	Baseline, Tx Endpoint, Each of 4 follow-up assessments	Randomized sample	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group62

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Panic Disorder Severity Scale (PDSS)	D-cycloserine	Baseline	13.30	Standard Deviation 4.50	units on a scale
Panic Disorder Severity Scale (PDSS)	Placebo	Baseline	13.37	Standard Deviation 3.39	units on a scale
Panic Disorder Severity Scale (PDSS)	D-cycloserine	TX Midpoint	7.98	Standard Deviation 3.92	units on a scale
Panic Disorder Severity Scale (PDSS)	Placebo	TX Midpoint	8.32	Standard Deviation 4.19	units on a scale
Panic Disorder Severity Scale (PDSS)	D-cycloserine	TX Endpoint	5.30	Standard Deviation 3.52	units on a scale
Panic Disorder Severity Scale (PDSS)	Placebo	TX Endpoint	6.43	Standard Deviation 4.63	units on a scale
Panic Disorder Severity Scale (PDSS)	D-cycloserine	Follow-Up 1	4.76	Standard Deviation 3.82	units on a scale
Panic Disorder Severity Scale (PDSS)	Placebo	Follow-Up 1	5.84	Standard Deviation 4.36	units on a scale
Panic Disorder Severity Scale (PDSS)	D-cycloserine	Follow-Up 2	4.38	Standard Deviation 3.50	units on a scale
Panic Disorder Severity Scale (PDSS)	Placebo	Follow-Up 2	4.53	Standard Deviation 4.03	units on a scale

1 to 10 of 62Source ClinicalTrials.gov

See all 62 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	D-cycloserine	88
Overall Study	STARTED	Placebo	92
Overall Study	COMPLETED	D-cycloserine	82
Overall Study	COMPLETED	Placebo	75
Overall Study	NOT COMPLETED	D-cycloserine	6
Overall Study	NOT COMPLETED	Placebo	17

Source ClinicalTrials.gov

Adverse events44

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nausea/vomiting	Gastrointestinal disorders	D-cycloserine	6	88
other	Nausea/vomiting	Gastrointestinal disorders	Placebo	7	92
other	Gastrointestinal distress	Gastrointestinal disorders	D-cycloserine	2	88
other	Gastrointestinal distress	Gastrointestinal disorders	Placebo	3	92
other	Headache	General disorders	D-cycloserine	4	88
other	Headache	General disorders	Placebo	3	92
other	Fatigue	General disorders	D-cycloserine	11	88
other	Fatigue	General disorders	Placebo	3	92
other	Sedation	General disorders	D-cycloserine	5	88
other	Sedation	General disorders	Placebo	3	92

1 to 10 of 44Source ClinicalTrials.gov

See all 44 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	D-cycloserine	0	88
Total, all-cause mortality	Placebo	0	92
Total, other adverse events	D-cycloserine	17	88
Total, other adverse events	Placebo	18	92
Total, serious adverse events	D-cycloserine	1	88
Total, serious adverse events	Placebo	1	92

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
27315514	RESULT

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01MH081116	1/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder	OTTO, MICHAEL W.	BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)	NATIONAL INSTITUTE OF MENTAL HEALTH	2008 to 2012

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
D-cycloserine vs Placebo: deaths from any cause	Trial comparisons
D-cycloserine vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00790868

GET https://conductscience.org/api/trials/v1/NCT00790868/results?page=2

API reference For AI assistants